Semaglutide and Tirzepatide Cut Fall and Fracture Risk by ~50% in Older Diabetics
GLP-1 receptor agonists semaglutide and tirzepatide significantly reduced femoral fractures and falls in adults 65+ with type 2 diabetes compared to DPP-4 inhibitors.
Summary
A large retrospective study of over 40,000 older adults with type 2 diabetes found that semaglutide and tirzepatide were associated with roughly half the risk of femoral fractures and about one-third fewer falls compared to DPP-4 inhibitors over one year. Using a US real-world database and propensity score matching to reduce confounding, the study suggests these GLP-1-based medications may offer musculoskeletal benefits beyond blood sugar control. Fracture reductions were especially strong in patients with BMI of 30 or higher. These findings are particularly relevant for older adults, in whom falls and fractures are leading causes of disability and death, and suggest that drug choice in type 2 diabetes management may have meaningful downstream effects on aging-related injury risk.
Detailed Summary
Falls and hip or femoral fractures are among the most devastating consequences of aging, often triggering a rapid decline in functional independence and increasing mortality risk in older adults. Identifying diabetes medications that also protect musculoskeletal health could have major implications for how clinicians choose treatments in this vulnerable population.
This retrospective cohort study used the TriNetX database — a large real-world US health records system — to examine adults aged 65 and older with type 2 diabetes and a BMI of 25 or above treated between 2018 and 2025. Patients on semaglutide or tirzepatide were compared to those on DPP-4 inhibitors using 1:1 propensity score matching, yielding approximately 27,900 patients in the semaglutide comparison and 12,800 in the tirzepatide comparison. Primary outcomes were femoral fractures and falls over one year.
The results were striking. Femoral fracture rates were roughly half as common in the semaglutide group (0.3% vs. 0.5%; HR 0.488) and even lower with tirzepatide (0.2% vs. 0.4%; HR 0.452) compared to DPP-4 inhibitors. Fall risk was similarly reduced: about 3.6% versus 5.4–5.7% for both GLP-1 agents. These differences were highly statistically significant. Subgroup analyses showed fracture benefits were most pronounced in patients with BMI at or above 30, while fall reductions were consistent across all subgroups.
The likely mechanisms are multifactorial. GLP-1 receptor agonists promote weight loss, which may reduce mechanical load and improve balance. They may also have direct effects on bone metabolism and muscle preservation, though this requires further study.
Key caveats apply. This is a retrospective, observational design subject to residual confounding despite propensity matching. The summary is based on the abstract only, limiting access to full methodological details, and causal claims cannot be made.
Key Findings
- Semaglutide reduced femoral fracture risk by ~51% vs. DPP-4 inhibitors (HR 0.488) in adults 65+.
- Tirzepatide reduced femoral fracture risk by ~55% (HR 0.452) compared to DPP-4 inhibitors.
- Both drugs cut fall risk by roughly one-third over one year compared to DPP-4 inhibitors.
- Fracture benefits were strongest in patients with BMI ≥ 30; fall benefits were consistent across all subgroups.
- Findings suggest musculoskeletal protection from GLP-1 agents beyond glycemic control alone.
Methodology
Retrospective cohort study using the TriNetX US real-world database (2018–2025) including adults aged ≥65 with type 2 diabetes and BMI ≥25. 1:1 propensity score matching was used to balance groups, yielding ~27,900 patients in the semaglutide comparison and ~12,800 in the tirzepatide comparison. Primary outcome was 1-year femoral fracture; secondary outcome was 1-year fall rate.
Study Limitations
As a retrospective observational study, residual confounding cannot be excluded despite propensity score matching. Causal mechanisms cannot be established, and the database does not allow full control for factors such as baseline physical activity, bone density, or prior fall history. This summary is based on the abstract only, as the full text was not accessible.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: